Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
about
Novel antiplatelet agents in the prevention of cardiovascular complications--focus on ticagrelor.Ticagrelor: pharmacokinetics, pharmacodynamics, clinical efficacy, and safety.Ticagrelor: from discovery to Phase III clinical trial.Ticagrelor: a review of its use in the management of acute coronary syndromes.Prasugrel vs. ticagrelor in acute coronary syndromes: which one to choose?Clopidogrel resistance: identifying and overcoming a barrier to effective antiplatelet treatment.Pharmacokinetic, pharmacodynamic and pharmacogenetic profile of the oral antiplatelet agent ticagrelor.Ticagrelor: positive, negative and misunderstood properties as a new antiplatelet agent.The PlA1/A2 polymorphism of glycoprotein IIIa in relation to efficacy of antiplatelet drugs: a systematic review and meta-analysis.Platelet reactivity tests for assessing antiplatelet drug response: what the clinician needs to know.Pharmacology of the new P2Y12 receptor inhibitors: insights on pharmacokinetic and pharmacodynamic properties.Pharmacogenomics of oral antiplatelet drugs.Why we need intravenous antiplatelet agents.Pharmacokinetics and pharmacodynamics of ticagrelor in the treatment of cardiac ischemia.Pharmacokinetics and pharmacodynamics of ticagrelor when treating non-ST elevation acute coronary syndromes.Ticagrelor in modern cardiology - an up-to-date review of most important aspects of ticagrelor pharmacotherapy.Ticagrelor - toward more efficient platelet inhibition and beyond.Association of PEAR1 rs12041331 polymorphism and pharmacodynamics of ticagrelor in healthy Chinese volunteers.Comparison of pharmacodynamics between low dose ticagrelor and clopidogrel after loading and maintenance doses in healthy Korean subjects.
P2860
Q33902628-8BB5BEA9-5DC8-40C3-BCEA-966CE36E6C96Q34805121-AE3317D9-EDA0-443E-AB89-4DB094AC9EADQ37818206-443F627D-7F67-48A3-8FE4-10317CEDF52BQ37875063-22FD178C-26A8-46CF-912D-57AC57D4D8B5Q37907902-3DD93930-54B6-431F-AD28-ACA80D2E37BDQ37924998-6FA98B4B-1FE0-47E4-9339-A6763C08AD07Q38001453-B49A6279-9A58-4B65-AD60-A5224435BC8AQ38099380-6D688597-16D2-41F4-B9CF-1211153A079EQ38120047-98C93794-8B08-4469-A651-391168F24382Q38132252-B969639D-F269-4316-8FA8-C35C0C30FFDAQ38151563-BC999F34-D587-41B3-8B65-D332B7DBBB56Q38195628-8E348D58-0467-4B1A-84B7-7DF87F89A285Q38851769-E5B1D387-8CB2-4133-B5E8-BB6617D67A65Q38974884-748748EF-FABF-4336-8E8B-0B2B6E195DD6Q41060485-F9C49281-BA51-4ECC-9509-1888DBBF9F2EQ48344587-22B84854-B81C-4DC6-81D8-F2F4718B015DQ49337303-A1D02A17-AAA1-44BE-8114-E78B3421F193Q51019317-EE6FFE6D-13CD-4E94-82EA-BE7C0AED3128Q53257151-75088FE1-6EC4-448D-A23D-44295BA58FD6
P2860
Ticagrelor yields consistent dose-dependent inhibition of ADP-induced platelet aggregation in patients with atherosclerotic disease regardless of genotypic variations in P2RY12, P2RY1, and ITGB3.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Ticagrelor yields consistent d ...... s in P2RY12, P2RY1, and ITGB3.
@en
Ticagrelor yields consistent d ...... s in P2RY12, P2RY1, and ITGB3.
@nl
type
label
Ticagrelor yields consistent d ...... s in P2RY12, P2RY1, and ITGB3.
@en
Ticagrelor yields consistent d ...... s in P2RY12, P2RY1, and ITGB3.
@nl
prefLabel
Ticagrelor yields consistent d ...... s in P2RY12, P2RY1, and ITGB3.
@en
Ticagrelor yields consistent d ...... s in P2RY12, P2RY1, and ITGB3.
@nl
P2093
P2860
P1433
P1476
Ticagrelor yields consistent d ...... s in P2RY12, P2RY1, and ITGB3.
@en
P2093
Christopher P Cannon
Mark Wickens
Martin Armstrong
Rachael Lawrance
S Melissa Thornton
Stan Heptinstall
Steen Husted
P2860
P304
P356
10.1080/09537100903075324
P577
2009-08-01T00:00:00Z